Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
273.8 CHF | -0.29% | -0.92% | +4.74% |
06-28 | Swiss Market Index Closes Little Changed Amid Key European Inflation Data | MT |
06-28 | Roche's Eye Therapy Vabysmo Gets EU Panel's Nod for Additional Indication | MT |
Summary
- Overall, and from a short-term perspective, the company presents an interesting fundamental situation.
Strengths
- The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
Weaknesses
- With an enterprise value anticipated at 3.51 times the sales for the current fiscal year, the company turns out to be overvalued.
- The company appears highly valued given the size of its balance sheet.
- Over the past twelve months, analysts' opinions have been revised negatively.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+4.74% | 224B | - | ||
+55.32% | 815B | C+ | ||
+44.05% | 641B | B | ||
-6.75% | 352B | C+ | ||
+13.56% | 314B | B- | ||
+10.68% | 303B | C+ | ||
+16.57% | 242B | B+ | ||
+13.31% | 218B | B- | ||
+8.48% | 168B | C+ | ||
-2.81% | 159B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- ROG Stock
- 0QQ6 Stock
- Ratings Roche Holding AG